GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Enterprise Value

MedMira (MedMira) Enterprise Value : $54.86 Mil (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MedMira's Enterprise Value is $54.86 Mil. MedMira's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was $-1.40 Mil. Therefore, MedMira's EV-to-EBIT ratio for today is -39.15.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, MedMira's Enterprise Value is $54.86 Mil. MedMira's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was $-1.24 Mil. Therefore, MedMira's EV-to-EBITDA ratio for today is -44.31.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, MedMira's Enterprise Value is $54.86 Mil. MedMira's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 was $0.30 Mil. Therefore, MedMira's EV-to-Revenue ratio for today is 181.64.


MedMira Enterprise Value Historical Data

The historical data trend for MedMira's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Enterprise Value Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 219.20 71.64 76.14 49.21

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.19 52.19 49.21 14.54 30.58

Competitive Comparison of MedMira's Enterprise Value

For the Biotechnology subindustry, MedMira's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Enterprise Value distribution charts can be found below:

* The bar in red indicates where MedMira's Enterprise Value falls into.



MedMira Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

MedMira's Enterprise Value for the fiscal year that ended in Jul. 2023 is calculated as

MedMira's Enterprise Value for the quarter that ended in Jan. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (OTCPK:MMIRF) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

MedMira's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=54.856/-1.401
=-39.15

MedMira's current Enterprise Value is $54.86 Mil.
MedMira's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

MedMira's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=54.856/-1.238
=-44.31

MedMira's current Enterprise Value is $54.86 Mil.
MedMira's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.24 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

MedMira's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=54.856/0.302
=181.64

MedMira's current Enterprise Value is $54.86 Mil.
MedMira's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira Enterprise Value Related Terms

Thank you for viewing the detailed overview of MedMira's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023

MedMira Announces Product Update

By GlobeNewswire GlobeNewswire 12-31-2020

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019

MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

By ACCESSWIRE ACCESSWIRE 10-14-2022

Progress Update on Securities

By ACCESSWIRE 08-31-2023

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018